Get the Stockscreener App
1.30
11.11%
0.13
After Hours:
1.30
Nektar Therapeutics stock is traded at $1.30, with a volume of 1.28M.
It is up +11.11% in the last 24 hours and up +1.56% over the past month.
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
See More
Previous Close:
$1.17
Open:
$1.21
24h Volume:
1.28M
Relative Volume:
0.90
Market Cap:
$214.84M
Revenue:
$90.12M
Net Income/Loss:
$-276.06M
P/E Ratio:
-0.7975
EPS:
-1.63
Net Cash Flow:
$-193.47M
1W Performance:
+8.33%
1M Performance:
+1.56%
6M Performance:
+39.16%
1Y Performance:
+118.27%
1-Day Range:
$1.205
$1.335
1-Week Range:
$1.11
$1.335
52-Week Range:
$0.4126
$1.928
Nektar Therapeutics Stock (NKTR) Company Profile
Name
Nektar Therapeutics
Sector
Industry
Phone
(415) 482-5300
Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-10-23 | Upgrade | Jefferies | Underperform → Hold |
| Feb-24-23 | Downgrade | Jefferies | Hold → Underperform |
| Aug-08-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-31-22 | Resumed | Jefferies | Hold |
| Apr-18-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-15-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-15-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-14-22 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-14-22 | Downgrade | Stifel | Buy → Hold |
| Mar-14-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-08-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-21 | Initiated | BofA Securities | Neutral |
| Jun-28-21 | Upgrade | Stifel | Hold → Buy |
| May-18-21 | Resumed | Goldman | Neutral |
| Feb-22-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jan-06-21 | Initiated | Stifel | Hold |
| Sep-14-20 | Initiated | JP Morgan | Neutral |
| Jun-10-20 | Downgrade | CFRA | Hold → Sell |
| May-12-20 | Reiterated | H.C. Wainwright | Neutral |
| Apr-22-20 | Initiated | The Benchmark Company | Buy |
| Mar-30-20 | Upgrade | Goldman | Sell → Neutral |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-03-20 | Upgrade | Mizuho | Neutral → Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-08-19 | Downgrade | Goldman | Buy → Sell |
| Aug-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-09-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-09-19 | Downgrade | Mizuho | Buy → Neutral |
| Mar-15-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-13-18 | Initiated | Goldman | Buy |
| Jun-11-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-04-18 | Reiterated | H.C. Wainwright | Buy |
| Apr-20-18 | Initiated | Seaport Global Securities | Buy |
| Apr-13-18 | Resumed | Piper Jaffray | Overweight |
| Apr-06-18 | Reiterated | Mizuho | Buy |
| Apr-02-18 | Resumed | H.C. Wainwright | Buy |
View All
Nektar Therapeutics Stock (NKTR) Latest News
BTIG upgrades Nektar stock, sees upside on Rezpeg potential - Investing.com India
Nektar rises 11% as BTIG initiates buy rating on autoimmune disorders asset - Seeking Alpha
BTIG Research Reiterates "Buy" Rating for Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat
Renaissance Technologies LLC Sells 1,306,848 Shares of Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat
836,000 Shares in Nektar Therapeutics (NASDAQ:NKTR) Acquired by Armistice Capital LLC - MarketBeat
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024 - cnhinews.com
Samlyn Capital LLC Makes New $11.73 Million Investment in Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat
Market Momentum Report: Nkarta Inc (NKTX)’s Negative Close at 5.21 - The Dwinnex
Raymond James Upgrades Nkarta Inc (NKTX) to a Strong buy from an Outperform - Knox Daily
Taking a Closer Look At Nerdy Inc (NRDY) Following Its Recent Trade - Knox Daily
ARS Pharmaceuticals Announces U.S. Availability of neffy® - GlobeNewswire
Federated Hermes Inc. Boosts Stock Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Bank of New York Mellon Corp Grows Stock Position in Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat
Neon City Festival announces headliners at Fremont - Fox 5 Las Vegas
Meta platforms' chief legal officer sells shares worth over $486k - Investing.com India
Primecap Management Co. CA Has $7.47 Million Stock Holdings in Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat
Neat further reduces London estate as co-founder departs business - Restaurant
Nektar Therapeutics (NASDAQ:NKTR) Shares Sold by Acadian Asset Management LLC - MarketBeat
Acadian Asset Management LLC Sells 2,684,469 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Candriam S.C.A. Takes $99,000 Position in Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Nektar Management to Present at Upcoming Investor Conferences - Kilgore News Herald
Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of “Hold” by Brokerages - Defense World
Monaco Asset Management SAM Sells 3,665,133 Shares of Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat
What Makes Nektar (NKTR) a New Buy Stock - MSN
Nektar Therapeutics' (NASDAQ:NKTR) institutional investors lost 12% over the past week but have profited from longer-term gains - Simply Wall St
Nektar Management to Present at Upcoming Investor Conferences - StockTitan
Nektar Management to Present at Upcoming Investor Conferences - Yahoo Finance
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates - MSN
Nektar Can't Get Docs It Says Show Lilly As 'Thieves, Liars' - Law360
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top - MSN
Nektar Therapeutics Reports Second Quarter 2024 Financial Results - Longview News-Journal
Nektar Therapeutics exec sells shares to cover tax By Investing.com - Investing.com Australia
Nektar Therapeutics CEO sells shares worth over $19,000 By Investing.com - Investing.com Australia
Nektar Therapeutics executive sells shares to cover tax By Investing.com - Investing.com Australia
Nektar Therapeutics CEO sells shares worth over $19,000 - Investing.com India
Howard W. Robin Sells 14,881 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock - MarketBeat
Nektar Therapeutics CEO sells shares worth over $19,000 - Investing.com
Nektar Therapeutics executive sells shares to cover tax - Investing.com
Nektar Therapeutics exec sells shares to cover tax - Investing.com
Nektar Therapeutics CEO sells shares worth over $19,000 By Investing.com - Investing.com Canada
Nektar Therapeutics executive sells shares to cover tax By Investing.com - Investing.com UK
Values First Advisors Inc. Makes New Investment in Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Nektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of “Hold” by Analysts - Defense World
Nektar Therapeutics (NASDAQ:NKTR) Share Price Crosses Above Two Hundred Day Moving Average of $1.18 - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Shares Pass Above 200-Day Moving Average of $1.18 - Defense World
What Makes Nektar (NKTR) a New Buy Stock - Yahoo Canada Finance
What Makes Nektar (NKTR) a New Buy Stock - Yahoo Finance
Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript - Seeking Alpha
Nektar Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Nektar Therapeutics Stock (NKTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):